279 related articles for article (PubMed ID: 26794392)
1. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
2. GOLPH3 and YB-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
El-Maqsoud NMRA; Osman NAA; El-Hamid AMA; El-Bab TKF; Galal EM
World J Oncol; 2015 Dec; 6(6):473-484. PubMed ID: 28983350
[TBL] [Abstract][Full Text] [Related]
3. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
Hua X; Yu L; Pan W; Huang X; Liao Z; Xian Q; Fang L; Shen H
Diagn Pathol; 2012 Sep; 7():127. PubMed ID: 23006319
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer.
Shiraiwa S; Kinugasa T; Kawahara A; Mizobe T; Ohchi T; Yuge K; Fujino S; Katagiri M; Shimomura S; Tajiri K; Sudo T; Kage M; Kuwano M; Akagi Y
Anticancer Res; 2016 Jul; 36(7):3781-8. PubMed ID: 27354655
[TBL] [Abstract][Full Text] [Related]
6. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta 1 and androgen receptors in prostate neoplasia.
Cardillo MR; Petrangeli E; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Oct; 22(5):403-10. PubMed ID: 11064817
[TBL] [Abstract][Full Text] [Related]
9. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression.
Ferronika P; Triningsih FX; Ghozali A; Moeljono A; Rahmayanti S; Shadrina AN; Naim AE; Wudexi I; Arnurisa AM; Nanwani ST; Harijadi A
Asian Pac J Cancer Prev; 2012; 13(5):1943-8. PubMed ID: 22901151
[TBL] [Abstract][Full Text] [Related]
10. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
11. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer.
Li R; Erdamar S; Dai H; Wheeler TM; Frolov A; Scardino PT; Thompson TC; Ayala GE
Hum Pathol; 2007 Oct; 38(10):1501-7. PubMed ID: 17597184
[TBL] [Abstract][Full Text] [Related]
12. Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.
Hong H; Kao C; Jeng MH; Eble JN; Koch MO; Gardner TA; Zhang S; Li L; Pan CX; Hu Z; MacLennan GT; Cheng L
Cancer; 2004 Jul; 101(1):83-9. PubMed ID: 15221992
[TBL] [Abstract][Full Text] [Related]
13. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
14. Role of androgen receptor in prostatic neoplasia versus hyperplasia.
Husain I; Shukla S; Soni P; Husain N
J Cancer Res Ther; 2016; 12(1):112-6. PubMed ID: 27072221
[TBL] [Abstract][Full Text] [Related]
15. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific G protein coupled receptor is associated with prostate cancer prognosis and affects cancer cell proliferation and invasion.
Cao W; Li F; Yao J; Yu J
BMC Cancer; 2015 Nov; 15():915. PubMed ID: 26582057
[TBL] [Abstract][Full Text] [Related]
18. FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
Imada K; Shiota M; Kuroiwa K; Sugimoto M; Abe T; Kohashi K; Yokomizo A; Eto M; Naito S; Oda Y
Prostate; 2017 Feb; 77(2):145-153. PubMed ID: 27699813
[TBL] [Abstract][Full Text] [Related]
19. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
20. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.
Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y
Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
